These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15972368)

  • 21. Cerivastatin and the dissemination of adverse event information.
    Weaver SJ; Doering PL
    Ann Pharmacother; 2002 Jun; 36(6):1099-103. PubMed ID: 12058704
    [No Abstract]   [Full Text] [Related]  

  • 22. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 23. Five fixes to improve drug safety. Ideas for how to prevent another Vioxx debacle.
    Thygeson M
    Minn Med; 2005 Dec; 88(12):36-7. PubMed ID: 16583524
    [No Abstract]   [Full Text] [Related]  

  • 24. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.
    Ball R; Robb M; Anderson SA; Dal Pan G
    Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse Event Reports Associated with Vaginal Mesh: An Interrupted Time Series Analysis.
    Leiter V; White SK; Walters A
    Womens Health Issues; 2017; 27(3):279-285. PubMed ID: 28233636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [FDA's new drug approval system].
    Ishii A
    Gan To Kagaku Ryoho; 1995 Aug; 22(9):1146-51. PubMed ID: 7661565
    [No Abstract]   [Full Text] [Related]  

  • 29. JCAHO views medication reconciliation as adverse-event prevention.
    Thompson CA
    Am J Health Syst Pharm; 2005 Aug; 62(15):1528, 1530, 1532. PubMed ID: 16030354
    [No Abstract]   [Full Text] [Related]  

  • 30. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 31. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data.
    Sarangdhar M; Tabar S; Schmidt C; Kushwaha A; Shah K; Dahlquist JE; Jegga AG; Aronow BJ
    Nat Biotechnol; 2016 Jul; 34(7):697-700. PubMed ID: 27404875
    [No Abstract]   [Full Text] [Related]  

  • 32. Commentary on "Secondary use of electronic health record data: spontaneous triggered adverse drug event reporting" by Linder et al.
    Dal Pan GJ
    Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1216-7. PubMed ID: 20981885
    [No Abstract]   [Full Text] [Related]  

  • 33. [Notification systems and adverse effect reporting].
    Aranaz Andrés JM
    Rev Calid Asist; 2009 Feb; 24(1):1-2. PubMed ID: 19369135
    [No Abstract]   [Full Text] [Related]  

  • 34. Handling adverse event reports.
    Rich S
    Nursing; 2000 Nov; 30(11):78. PubMed ID: 11111664
    [No Abstract]   [Full Text] [Related]  

  • 35. [A revolutionary idea: employ five adverse event managers, then clinicians will be happy!].
    Madsen F
    Ugeskr Laeger; 2012 Nov; 174(46):2881. PubMed ID: 23320259
    [No Abstract]   [Full Text] [Related]  

  • 36. Likelihood ratio test-based method for signal detection in drug classes using FDA's AERS database.
    Huang L; Zalkikar J; Tiwari RC
    J Biopharm Stat; 2013; 23(1):178-200. PubMed ID: 23331230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system.
    Raisch DW; Rafi JA; Chen C; Bennett CL
    Expert Opin Drug Saf; 2016 Aug; 15(8):1003-11. PubMed ID: 27268272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consumer groups look to improve adverse event reporting systems.
    Vastag B
    J Natl Cancer Inst; 2005 Dec; 97(24):1804-5. PubMed ID: 16368939
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA's Investigation into Patients Being Injected with Simulated IV Fluids Continues.
    Ohio Nurses Rev; 2015; 90(1):6-7. PubMed ID: 26477080
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug recalls and notification of practitioners.
    Rodts MF
    Orthop Nurs; 2004; 23(6):353-4. PubMed ID: 15682877
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.